Back to Awarded Treatment Trials
Awarded Trial: 08TGF-1193
Grant ID
08TGF-1193
Illness
Schizophrenia
Primary Drug/Intervention
Varenicline
Primary Dosage
0.5-2 mg/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Smith
Sample Size
60
Duration of Study Period for Each Subject
94
Outcome Measurements
PANSS, HAM-D, MATRICS Battery SANS
Results
92 patients with a diagnosis of schizophrenia or schizoaffective psychosis being treated with antipsychotic medication, and who were cigarette smokers, were randomized to receive 2mg/day varenicline or placebo for 8 weeks. The study was designed to measure the effects of varenicline on measures of smoking, cognition, psychopathology and side effects. Although varenicline significantly reduced smoking in schizophrenic patients, there were no differences in cognitive function, psychopathology scores or side-effects.
Publication
N/A
Link
N/A
PI Name
Robert Smith
Degree
MD
Center
N/A
Institution
Research Foundation for Mental Hygiene, Inc.
Address
PO box 316
City or Town
Hewlett
State or Province
NY
Zip or Postal Code
11557
Country
USA
Email Address
robert.smith@med.nyu.edu